

ANRS CO23 CUPILT - Cohort of Liver Transplant Patients with Hepatitis C Recurrence Treated with Direct Acting Antiviral Agent

Head :Pageaux Georges-Philippe

Duclos Vallée Jean-Charles, Joint Research Unit U785

Coilly Audrey, Joint Research Unit U785

Last update : 06/29/2016 | Version : 1 | ID : 73116

General

Identification

Detailed name	Cohort of Liver Transplant Patients with Hepatitis C Recurrence Treated with Direct Acting Antiviral Agent
---------------	--

Sign or acronym	ANRS CO23 CUPILT
-----------------	------------------

General Aspects

Medical area	Biology Gastroenterology et hepatology Infectious diseases
--------------	--

Health determinants	Iatrogenic Medicine
---------------------	------------------------

Keywords	drug interactions, direct acting antivirals, liver transplant, HCV
----------	--

Scientific investigator(s) (Contact)

Name of the director	Pageaux
Surname	Georges-Philippe
Address	CHRU Saint Eloi 80 av Augustin Fliche 34295 MONTPELLIER CEDEX 5
Phone	+33 (0)4 67 33 73 90
Email	gp-pageaux@chu-montpellier.fr
Organization	Montpellier University Hospital

Name of the director	Duclos Vallée
Surname	Jean-Charles

Address	12-14 Avenue Paul Vaillant Couturier 94800 Villejuif
Phone	+33 (0)1 45 59 32 55
Email	jean-charles.duclos-vallee@pbr.aphp.fr
Unit	Joint Research Unit U785
Organization	Paul Brousse Hepatobiliary Centre

Name of the director	Coilly
Surname	Audrey
Address	12-14 Avenue Paul Vaillant Couturier 94800 Villejuif
Phone	+33 (0)1 45 59 33 36
Email	audrey.coilly@pbr.aphp.fr
Unit	Joint Research Unit U785
Organization	Paul Brousse Hepatobiliary Centre

Collaborations
Funding

Funding status	Public
----------------	--------

Details	ANRS, Inserm
---------	--------------

Governance of the database

Sponsor(s) or organisation(s) responsible	Inserm-ANRS
Organisation status	Public

Sponsor(s) or organisation(s) responsible	Service d'Hépatogastroentérologie, Hôpital Saint-Eloi, Montpellier
Organisation status	Public

Sponsor(s) or organisation(s) responsible	Centre Hépto-Biliaire Paul Brousse
Organisation status	Public

Presence of scientific or	Yes
---------------------------	-----

steering committees

Additional contact

Main features

Type of database

Type of database

Study databases

Study databases (details)

Cohort study

Database recruitment is carried out by an intermediary

A selection of health institutions and services

Database recruitment is made on the basis of:

Medication(s) taken

Database recruitment is carried out as part of an interventional study

Yes

Details

Performed at individual level

Database objective

Main objective

To investigate the efficacy, defined as obtaining a sustained virology response after 12 weeks of completing treatment, of direct acting agents (DAA) with or without peginterferon and/or ribavirin therapy, in liver transplant patients with Hepatitis C virus (HCV) infection recurrence following liver transplantation, regardless of genotype or response to previous treatment.

Inclusion criteria

? elderly subjects over 18 years old
? transplanted liver
? infected with HCV before transplantation
? presenting Hepatitis C virus (HCV) infection recurrence (regardless of genotype) with detectable HCV RNA at baseline
? received or receiving antiviral therapy with a direct antiviral agent or having completed treatment but still being monitored (within 48 weeks after completing treatment)
? member of a social security scheme
? signed consent form

N.B.: Included

? multiple transplants
? treatment-naïve or failed treatment patients, before and after transplantation, regardless of previous model

? patients with HIV or HBV co-infection
? all stages of hepatic fibrosis

Population type

Age
Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered Sick population

Gender
Male
Woman

Geography area International

Detail of the geography area France and Belgium

Data collection

Dates

Date of first collection (YYYY or MM/YYYY) 10/2013

Date of last collection (YYYY or MM/YYYY) 06/2018

Size of the database

Size of the database (number of individuals) [500-1000[individuals

Details of the number of individuals 800

Data

Database activity Current data collection

Type of data collected
Clinical data
Biological data

Clinical data (detail)
Direct physical measures
Medical registration

Details of collected clinical data
Year of birth; sex; details of ethnicity and skin colour; unresolved medical comorbidities at baseline; details regarding pre-transplantation; donor; transplantation; details regarding post-

	transplantation treatments and complications; height; weight; treatment tolerance; treatments (? immunosuppressants (collected up to 4 weeks following DAA treatment completion) ? antiretroviral treatment ? hematopoietic growth factors ? corrective action plans for adverse effects and Grade 3 serious adverse effects ? any other treatments deemed significant by the investigator)
Biological data (detail)	FBC; INR platelets; Albumin; TP; ALT; AST; GGT PAL; total bilirubin; RNA and HCV; residual immunosuppressive concentration; if HIV+: Viral load and CD4 count
Presence of a biobank	Yes
Contents of biobank	Serum Plasma Blood cells isolated
Details of biobank content	Plasma and serum for DNA extraction and cell bank.
Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services
Care consumption (detail)	Medical/paramedical consultation Medicines consumption
Procedures	
Participant monitoring	Yes
Details on monitoring of participants	Treatment duration and 48 weeks following treatment completion.
Links to administrative sources	No
Promotion and access	
Promotion	
Link to the document	http://tinyurl.com/pubmed-ANRSCO23
Access	
Terms of data access (charter for data provision, format of data, availability delay)	Contact the scientist in charge and Inserm?ANRS sponsor.
Access to aggregated data	Access on specific project only

Access to individual data

Access on specific project only